These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12815598)

  • 1. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1.
    Southey MC; Tesoriero A; Young MA; Holloway AJ; Jenkins MA; Whitty J; Misfud S; kConFab ; McLachlan SA; Venter DJ; Armes JE
    Hum Mutat; 2003 Jul; 22(1):86-91. PubMed ID: 12815598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain.
    Campos B; Díez O; Domènech M; Baena M; Balmaña J; Sanz J; Ramírez A; Alonso C; Baiget M
    Hum Mutat; 2003 Oct; 22(4):337. PubMed ID: 12955719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2.
    Claes K; Poppe B; Machackova E; Coene I; Foretova L; De Paepe A; Messiaen L
    Genes Chromosomes Cancer; 2003 Jul; 37(3):314-20. PubMed ID: 12759930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression.
    Chen X; Truong TT; Weaver J; Bove BA; Cattie K; Armstrong BA; Daly MB; Godwin AK
    Hum Mutat; 2006 May; 27(5):427-35. PubMed ID: 16619214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
    Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
    Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany.
    Meyer P; Voigtlaender T; Bartram CR; Klaes R
    Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
    Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
    Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs.
    Vreeswijk MP; Kraan JN; van der Klift HM; Vink GR; Cornelisse CJ; Wijnen JT; Bakker E; van Asperen CJ; Devilee P
    Hum Mutat; 2009 Jan; 30(1):107-14. PubMed ID: 18693280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
    Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
    BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families.
    Rothfuss A; Schütz P; Bochum S; Volm T; Eberhardt E; Kreienberg R; Vogel W; Speit G
    Cancer Res; 2000 Jan; 60(2):390-4. PubMed ID: 10667592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA2 founder mutation in Slovenian breast cancer families.
    Krajc M; De Grève J; Goelen G; Teugels E
    Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3030-4. PubMed ID: 16324400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
    Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
    Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts.
    Gutiérrez-Enríquez S; Coderch V; Masas M; Balmaña J; Diez O
    Breast Cancer Res Treat; 2009 Sep; 117(2):461-5. PubMed ID: 18712473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA-based analysis of BRCA1 and BRCA2 gene alterations.
    Bonatti F; Pepe C; Tancredi M; Lombardi G; Aretini P; Sensi E; Falaschi E; Cipollini G; Bevilacqua G; Caligo MA
    Cancer Genet Cytogenet; 2006 Oct; 170(2):93-101. PubMed ID: 17011978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.